1799811-83-8

Basic information

• Product Name: 1-(tert-butyl) 2-methyl (R)-4-oxopiperidine-1,2-dicarboxylate
• Synonyms: 1-(tert-butyl) 2-methyl (R)-4-oxopiperidine-1,2-dicarboxylate;1,2-Piperidinedicarboxylic acid, 4-oxo-, 1-(1,1-dimethylethyl) 2-methyl ester, (2R)-
• CAS NO: 1799811-83-8
• Molecular Formula: C12H19NO5
• Molecular Weight: 257.28296
• EINECS: -0
• Mol File: 1799811-83-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-(tert-butyl) 2-methyl (R)-4-oxopiperidine-1,2-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(tert-butyl) 2-methyl (R)-4-oxopiperidine-1,2-dicarboxylate(1799811-83-8)
• EPA Substance Registry System: 1-(tert-butyl) 2-methyl (R)-4-oxopiperidine-1,2-dicarboxylate(1799811-83-8)

Safety Data

• Hazardous Substances Data: 1799811-83-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(tert-butyl) 2-methyl (R)-4-oxopiperidine-1,2-dicarboxylate is used as a pharmaceutical intermediate for its potential role in drug development. Its reactivity and structural features make it a valuable component in the synthesis of new medicinal compounds, contributing to the creation of innovative treatments and therapies.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(tert-butyl) 2-methyl (R)-4-oxopiperidine-1,2-dicarboxylate serves as a key building block. Its presence of multiple functional groups facilitates its incorporation into a wide array of organic molecules, enhancing the diversity and complexity of synthesized compounds for various applications, including but not limited to materials science, agrochemicals, and specialty chemicals.

Upstream product

• 38053-91-7 2-trimethylsilyloxy-1,3-butadiene 
• 81357-15-5 [(E)-tert-Butoxycarbonylimino]-acetic acid methyl ester 
• 26250-84-0 (S)-(-)-1-(tert-butoxycarbonyl)-2-piperidinecarboxylic acid 
• 74-88-4 methyl iodide 
• 198646-60-5 (2R)-1-(tert-butoxycarbonyl)-4-oxopiperidine-2-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 198646-60-5 (S)-1-(tertbutyloxycarbonyl)-4-oxo-piperidine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 187753-15-7 (2S)-4-oxopipecolic acid methyl ester 
• 144913-66-6 4-hydroxy-2-piperidine carboxylic acid methyl ester 
• 187753-13-5 N-tert-butoxycarbonyl-cis-4-hydroxy-L-pipecolinic acid methyl ester 
• 68014-21-1 triphenyl(t-butoxycarbonylimino)phosphorane 

Downstream Products

• 1448668-16-3 C₂₀H₃₀N₂O₄ 
• 1448668-15-2 C₂₀H₃₀N₂O₄ 
• 1352342-07-4 (S)-1-tert-butyl 2-methyl-4-oxopiperidine-1,2-dicarboxylate 
• 417726-36-4 (S)-1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridine-2-carboxylic acid 

Relevant articles and documents

Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT

A previous publication from our laboratory reported the identification of a new class of 2-(1H-imidazo-2-yl)piperazines as potent T. brucei growth inhibitors as potential treatment for Human African Trypanosomiasis (HAT). This work describes the structure–activity relationship (SAR) around the hit compound 1, which led to the identification of the optimized compound 18, a single digit nanomolar inhibitor (EC50 7 nM), not cytotoxic and with optimal in vivo profile that made it a suitable candidate for efficacy studies in a mouse model mimicking the second stage of disease.

(R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION

There is described a compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)- cyclopropyl)benzoic acid or a pharmaceutically acceptable salt thereof or the form A of its sodium salt for use in the prevention of heterotopic ossification. Preferably such a compound is effective in a specific dose range.

PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS

The present invention provides a pharmaceutical combination comprising the EP4 antagonist of Formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5- carboxamido)cyclopropyl)-benzoic acid or a pharmaceutically acceptable salt thereof and at least one immune checkpoint inhibitor, preferably the sodium salt of (R)-4-(1- (6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid. A polymorphic form A of sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl) benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2θ ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9 is also described. The combination and the polymorphic form A are described for use in the treatment of tumours.

SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION

The present invention relates to a class of novel heterocyclic compounds, to pharmaceutical compositions comprising the compounds and their use in the treatment of kinetoplastid infections.

NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND

This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.

Heterocyclic acylamide derivative and preparation method and pharmaceutical application thereof

The invention relates to a heterocyclic acylamide derivative and a preparation method and pharmaceutical application thereof, in particular to a heterocyclic acylamide derivative shown as a general formula (I) or a stereoisomer and a pharmaceutically-acce

Substituted piperidine amide derivative, preparation method thereof, and application of derivative to pharmacy

The invention relates to a substituted piperidine amide derivative as shown in a general formula (I) or a stereisomer and pharmaceutically acceptable salt thereof, a preparation method of the derivative, medicinal combination as well as application of the derivative to the aspects of local anaesthesia or analgesia. The definition of each group of the general formula (I) is consistent with that of the description. (The general formula (I) is as shown in the description).

PDD AND BPD COMPOUNDS

The invention relates to pyrridinobenzodiazepines (PDDs) comprising three fused 6-7- 6–membered rings and to benzopyrridodiazecines (BPDs) comprising three fused 6-8- 6–membered rings and, in particular, to PDD or BPD dimers linked together or PDD and BPD monomers linked to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, such as anti-proliferative agents. PDDs and BPDs may be represented by formula (I): and salts or solvates thereof, wherein R2, R4-R6 and R8 are independently selected substituent groups; and either: (i) R9 and R10 together form a double bond; (ii) R9 is H and R10 is OH; or (iii) R9 is H and R10 is ORA and RA is C1-6 alkyl; wherein each of m, n, u and w may be 0 or 1; where (a) the compound is a dimer with each monomer being the same or different and being of formula (I) where one of R1, R2, R3 and R7 of the first monomer and one of R'1, R'2, R3 and R'7 of the second monomer form together a bridge having the formula –X-L-X'- linking the monomers and m + n + u + w = 1; or (b) a dimer and one of R1, R2 and R3 of the first monomer and one of R'1, R'2 and R3 of the second monomer form together a bridge having the formula –X-L-X'- linking the monomers and m = n = u = w = o; or (c) one of R1, R2, R3 and R7 has the formula: –X- L-X'-D or -(CH2)f-O-R14 and m + n + u + w = o or 1; or (d) R7 has the formula: –X-L-X'- D or -(CH2)g-O -15 and m + n + u + w = 1; and X-L-X'- is a linker group and D has the formula (II) or (III):

PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS

The present invention provides a compound of the Formula (I): wherein X, R, R1,R2,R3, R4,R5,R6, R7, R8, and R9 are as defined herein, or a pharmaceutically acceptable salt thereof.